M

MacroGenics
D

MGNX

1.51000
USD
-0.07
(-4.13%)
مغلق
حجم التداول
8,914
الربح لكل سهم
-3
العائد الربحي
-
P/E
-2
حجم السوق
95,266,388
أصول ذات صلة
ABBV
ABBV
0.810
(0.44%)
183.260 USD
AZN
AZN
-0.110
(-0.16%)
70.410 USD
BMY
BMY
-0.140
(-0.30%)
46.870 USD
GILD
GILD
0.670
(0.63%)
107.390 USD
INCY
INCY
-0.250
(-0.39%)
64.250 USD
MRK
MRK
-0.220
(-0.28%)
77.600 USD
N
NKTR
0.00400
(0.62%)
0.64810 USD
PFE
PFE
0.110
(0.47%)
23.330 USD
المزيد
الأخبار المقالات

العنوان: MacroGenics

القطاع: Healthcare
الصناعة: Biotechnology
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.